Related references
Note: Only part of the references are listed.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma
Xiulan Xue et al.
INFECTIOUS AGENTS AND CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Michael J. Flynn et al.
HEPATOLOGY (2019)
Comparison of the current international guidelines on the management of HCC
Friedrich Foerster et al.
JHEP REPORTS (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Liver cancer incidence and mortality in China: Temporal trends and projections to 2030
Rongshou Zheng et al.
CHINESE JOURNAL OF CANCER RESEARCH (2018)
Update in global trends and aetiology of hepatocellular carcinoma
Prashanth Rawla et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2018)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
Shukui Qin et al.
ONCOLOGIST (2014)
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma
Pengyuan Yang et al.
NATIONAL SCIENCE REVIEW (2014)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy, Safety, and Biomarkers of Single- Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
Valerie Boige et al.
ONCOLOGIST (2012)
Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC Results from the Phase IV MO19390 (SAiL) Study
Chun-Ming Tsai et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Christina L. Roland et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
Richard S. Finn et al.
LIVER INTERNATIONAL (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
WY Lau et al.
ANNALS OF SURGERY (2001)
Share Paper
